EMCDDA Risk Assessments are publications examining the health and social risks of individual new psychoactive substances.

This publication presents the data and findings of the risk assessment on N-(1‑phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 22 February 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 25 September 2017, the Council decided that acryloylfentanyl should be subject to control measures across the Member States.

Acryloylfentanyl is known from the scientific literature and is a close structural relative of fentanyl. Fentanyl is a fast but short-acting synthetic opioid.

Table of contents:
• EMCDDA actions on monitoring and responding to new drugs
• EMCDDA–Europol Joint Report on acryloylfentanyl: a summary
• Risk Assessment Report of a new psychoactive substance: acryloylfentanyl
• Annex 1: Technical report on acryloylfentanyl
• Council Decision on subjecting acryloylfentanyl to control measures
• Participants of the risk assessment meeting